Skip to main content

Table 1 Search terms for systematic review

From: Economic evaluations of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in type 2 diabetic nephropathy: a systematic review

Search terms MEDLINE EMBASE
Drug Mesh: Angiotensin-Converting Enzyme Inhibitors; Angiotensin Receptor Antagonists; EMtree: dipeptidyl carboxypeptidase inhibito; angiotensin receptor antagonist;
TIAB (Title and Abstract): ACEIs; ARBs; ACEI; ARB; renin angiotensin system inhibitor*a; renin angiotensin aldosterone system inhibitor*; ACE inhibitor*; RAS inhibitor*; RAAS inhibitor*; angiotensin converting enzyme inhibitor*; renin angiotensin system inhibitor*; angiotensin receptor blocker*; Losartan; Candesartan; Valsartan; Irbesartan; Telmisartan; Eprosartan; Olmesartan; Azilsartan; Benazepril; Captopril; Enalapril; Fosinopril; Lisinopril; Moexipril; Perindopril; Quinapril; Ramipril; Trandolapril ab,ti (Abstract and Title): angiotensin receptor blocker; angiotensin receptor blockers; arb; arbs; ace inhibitor; ace inhibitors; angiotensin converting enzyme inhibitor; angiotensin converting enzyme inhibitors; angiotensin converting enzyme (ace) inhibitor; angiotensin converting enzyme (ace) inhibitors; acei; aceis; renin angiotensin system inhibitor; renin angiotensin system inhibitors; renin angiotensin system (ras) inhibitor; renin angiotensin system (ras) inhibitors; ras inhibitor; ras inhibitors; renin angiotensin aldosterone system inhibitor; renin angiotensin aldosterone system inhibitors; raas inhibitor; raas inhibitors; losartan; candesartan; valsartan; irbesartan; telmisartan; eprosartan; olmesartan; azilsartan; benazepril; captopril; enalapril; fosinopril; lisinopril; moexipril; perindopril; quinapril; ramipril; trandolapril;
Diabetic Nephropathy (DN) Mesh: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Kidney Failure, Chronic; EMtree: non insulin dependent diabetes mellitus; diabetic nephropathy;
TIAB: diabetic nephropathy*; diabetic renal disease*; diabetic kidney disease*; ab,ti: diabetic nephropathy; diabetic nephropathies; diabetic renal diseases; diabetic renal disease; diabetic kidney diseases; diabetic kidney disease
Economic Evaluation (EE) Mesh: Economics, Pharmaceutical; Costs and Cost Analysis; Drug Costs; Cost Savings; Cost of Illness; Cost-Benefit Analysis; EMtree: pharmacoeconomics; economic evaluation; drug cost; cost control; cost of illness; cost benefit analysis; cost effectiveness analysis;
TIAB: cost effect*; cost utility; cost benefit*; economic evaluation*; cost analys* ab,ti: cost effectiveness; cost utility; cost benefit; economic evaluation; economic evaluations; cost analys;
Search Strategy (“Drug Term 1”[Mesh] OR “Drug Term 2”[TIAB] …) AND (“DN Term 1”[Mesh] OR “DN Term 2”[TIAB] …) AND (“EE Term 1”[Mesh] OR “EE Term 2”[TIAB] …) (‘Drug Term 1’/exp OR ‘Drug Term 2’:ab,ti …) AND (‘DN Term 1’/exp OR ‘DN Term 2’:ab,ti …) AND (‘EE Term 1’/exp OR ‘EE Term 2’:ab,ti …) NOT [medline]/lim b
  1. a: An asterisk (*) following the word is the wildcard character, which means to search in MEDLINE for all terms that begin with a word; b: To exclude articles that can be found in MEDLINE.